0.79
-0.0619(-7.25%)
Currency In USD
| Previous Close | 0.85 |
| Open | 0.83 |
| Day High | 0.88 |
| Day Low | 0.77 |
| 52-Week High | 4.99 |
| 52-Week Low | 0.69 |
| Volume | 548,429 |
| Average Volume | 267,511 |
| Market Cap | 37.93M |
| PE | -0.57 |
| EPS | -1.39 |
| Moving Average 50 Days | 0.99 |
| Moving Average 200 Days | 1.33 |
| Change | -0.06 |
If you invested $1000 in Shattuck Labs, Inc. (STTK) since IPO date, it would be worth $40.92 as of July 01, 2025 at a share price of $0.792. Whereas If you bought $1000 worth of Shattuck Labs, Inc. (STTK) shares 3 years ago, it would be worth $179.95 as of July 01, 2025 at a share price of $0.792.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Apr 02, 2025 9:00 PM GMT
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for th
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
GlobeNewswire Inc.
Feb 20, 2025 2:00 PM GMT
– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study – – SL-325 receptor occupancy (RO) an
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
GlobeNewswire Inc.
Feb 13, 2025 9:30 PM GMT
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the t